Key Stats for UnitedHealth Stock
- Current Price: $379.09
- Target Price (Mid): ~$700
- Street Target: ~$475
- Potential Total Return: ~85%
- Annualized IRR: ~15% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
UnitedHealth Group (UNH) closed at $379.09 on September 11, down 2.37% on the day. The stock is still up for the year, but it has handed back most of the rally that followed July earnings, when shares touched a 52-week high near $460. Two days before that close, the company’s finance chief stood at a Wells Fargo conference and told investors the one thing they most wanted to hear: the medical cost improvement that drove the second-quarter beat has not faded. Shares slid anyway, on a reported sale of part of its Florida clinics.
The market keeps treating good news as a chance to take profits off a strong year, while management spends every appearance arguing the turnaround is not just holding but accelerating into 2027. Investors, still nursing 2025, are not yet paying up for it.
The Cost Trend the CFO Says Is Sticking
Asked whether the favorable first-half cost trends were still intact in the third quarter, CFO Wayne DeVeydt said he would not comment on Q3 results directly, then added: “that durability has not dissipated.” He said the company continues to see the momentum it saw coming out of Q2 running into the last two months. For a company whose entire 2024 and 2025 story was cost trends outrunning pricing, a CFO volunteering that the improvement is sticking is the closest a conference gets to a catalyst.
The second quarter gave that claim its foundation, and TIKR covered the beat, and the raised guide in July: adjusted EPS of $6.38 topped the Street by roughly 30%, and management lifted full-year 2026 adjusted EPS guidance to a range near $20. DeVeydt then separated what is working from what is not. Medicare Advantage is running toward the upper half of the 2% to 4% margin range set for the year. Medicaid is stabilizing: blended rate increases of 6% to 7% have come through as expected, and he called 2026 the trough year for Medicaid margins, tracking to the profitable end of the guided loss range with a move back toward breakeven in 2027.
See historical and forward estimates for UnitedHealth stock (It’s free!) >>>
The Focus Is Cost
Commercial is the soft spot, and management did not pretend otherwise. Margins held flat when the goal was expansion, with arbitration under the No Surprises Act adding roughly a full point of cost. DeVeydt framed that pressure as concentrated: by his account, about five provider companies drive roughly 60% of the disputed billing, and the fix needs a legislative change that the company is now lobbying Congress for.
Management laid out a multiyear plan to strip out administrative expense measured in billions, not hundreds of millions, using automation across claims, approvals, and back-office work, with Optum’s finance organization targeted to be largely automated by the end of next year. The same theme shows up publicly: on September 1, UnitedHealthcare disclosed it will drop prior authorization on roughly 1,700 procedure codes effective October 1, about 30% of its preapproval requirements. Management is also putting capital behind the confidence, roughly doubling planned 2026 buybacks to at least $5 billion from $2.5 billion while steering debt-to-cap toward 40% by the fourth quarter.
Bloomberg reported UnitedHealth sold an interest in part of its WellMed primary-care clinics in Florida, which sit inside Optum Health, to private equity firm TPG. DeVeydt said in a Bloomberg interview that the company did not need the money and wanted a local operating partner, and OptumHealth CEO Krista Nelson said the company is not exiting Florida and keeps ownership and upside. Investors still saw a divestiture of the exact value-based-care assets that dented profits last year, and sold first. The transaction has been reported with terms undisclosed, so the strategic read remains partly management’s characterization.
See how UnitedHealth performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $379.09
- Target Price (Mid): ~$700
- Potential Total Return: ~85%
- Annualized IRR: ~15% / year
See analysts’ growth forecasts and price targets for UnitedHealth stock (It’s free!) >>>
The mid-case values UnitedHealth near $700, about 85% above today’s price and an annualized return near 15% per year over roughly four years. Two drivers carry revenue, and neither is heroic: a mid-case revenue CAGR near 6%, well below the 11% ten-year historical rate, and a net income margin recovering to around 5%, still under the 6%-plus UNH earned before the 2024 cost break. The margin driver is the one DeVeydt keeps returning to, medical cost discipline plus the administrative takeout, not a return to double-digit top-line growth.
The upside is straightforward: if the cost trend holds and the G&A program delivers, earnings normalize off a depressed base, and the multiple has room to expand from a trough near 18 times forward earnings, a discount to a business the market paid up for over the prior decade. The downside does not need a model. The commercial arbitration drag depends on Congress, and the federal investigation into Medicare Advantage risk-adjustment coding is the variable that no valuation can price and the one that could break the thesis outright.
Wall Street sits closer to the market than to the model. The consensus mean target is about $475, with 16 Buys and 7 Outperforms against a single Sell among covering analysts, and both Wells Fargo and Bernstein reiterated Buy ratings the week of the conference at targets above the Street mean. The gap between the ~$475 average and the model’s ~$700 is the argument itself: the Street is pricing a competent recovery, the model is pricing recovery plus multiple normalization.
Conclusion
The next real test is the third-quarter print, expected in late October. DeVeydt has now said publicly that cost-trend durability held through the first two months of the quarter, so the bar is specific: an operating margin holding its recovery off the 4.2% 2025 trough would confirm the turnaround is structural rather than a single good quarter, while any slippage would reopen every question the stock has carried since 2024. The model target, the Street target, and the whole multiple argument resolve off that one line.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in UnitedHealth?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UnitedHealth, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track UnitedHealth alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze UnitedHealth on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
